Table 2. Safety and effectiveness with DCS and BMS in the pooled LEADERS FREE & LEADERS FREE II ARC-HBR subgroups.

Endpoints	ARC-HBR				Non-ARC-HBR				Interaction p-value
	BMS (N=975)	DCS (N=1,923)	Adjusted hazard ratio* (95% CI)	p-value	BMS (n=236)	DCS (n=501)	Adjusted hazard ratio* (95% CI)	p-value
Primary safety endpoint (composite of cardiac death, MI or definite/probable stent thrombosis)	132 (13.8%)	184 (9.8%)	0.72 (0.57-0.91)	0.006	19 (8.1%)	37 (7.5%)	1.07 (0.60-1.88)	0.828	0.206
Primary effectiveness endpoint (clinically driven target lesion revascularisation)	81 (8.8%)	112 (6.2%)	0.70 (0.52-0.94)	0.016	26 (11.2%)	27 (5.6%)	0.49 (0.29-0.84)	0.009	0.260
Cardiac death	56 (5.9%)	82 (4.4%)	0.77 (0.54-1.09)	0.145	5 (2.1%)	8 (1.6%)	0.83 (0.27-2.52)	0.737	0.908
Myocardial infarction	85 (9.1%)	116 (6.2%)	0.70 (0.53-0.93)	0.015	18 (7.7%)	29 (5.9%)	0.87 (0.48-1.58)	0.648	0.521
Definite/probable stent thrombosis	21 (2.2%)	39 (2.1%)	1.02 (0.59-1.77)	0.934	5 (2.1%)	8 (1.6%)	0.95 (0.30-3.1)	0.937	0.918
Definite or probable stent thrombosis or MI	90 (9.6%)	125 (6.7%)	0.71 (0.54-0.94)	0.017	19 (8.1%)	32 (6.5%)	0.92 (0.51-1.64)	0.771	0.435
All-cause mortality	95 (9.8%)	167 (8.8%)	0.96 (0.74-1.24)	0.738	10 (4.2%)	15 (3.0%)	0.74 (0.33-1.65)	0.460	0.549
*Adjusted using inverse probability of treatment weighting according to propensity score. ARC-HBR: Academic Research Consortium High Bleeding Risk; BMS: bare metal stent; CI: confidence interval; DCS: drug-coated stent; MI: myocardial infarction